Free tool
FAERS Monitor: Izervay
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217225 or its brand name (Izervay, Avacincaptad Pegol Sodium). Reports on generic versions are filed under their own applications.
Reports
352
Serious
141
40% of reports
Hospitalization
6
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- visual impairment26
- intercepted product preparation error25
- eye pain24
- no adverse event24
- needle issue23
- off label use22
- vision blurred22
- syringe issue18
- endophthalmitis16
- product temperature excursion issue16
- choroidal neovascularisation15
- intraocular pressure increased15
- eye inflammation14
- blindness transient13
- inappropriate schedule of product administration13
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 5 |
| 2024 | 110 |
| 2025 | 114 |
| 2026 | 123 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,807 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| choroidal neovascularisationSignal | 15 | 1064.3 | 645.7 | 14,629 |
| product temperature excursion issueSignal | 16 | 186.7 | 115.6 | 2,764 |
| endophthalmitisSignal | 16 | 159.8 | 98.9 | 2,363 |
| intercepted product preparation errorSignal | 25 | 121.6 | 83.3 | 2,867 |
| blindness transientSignal | 13 | 105.5 | 61.9 | 1,242 |
| eye inflammationSignal | 14 | 87.8 | 52.5 | 1,115 |
| intraocular pressure increasedSignal | 15 | 70.2 | 42.8 | 955 |
| syringe issueSignal | 18 | 61.5 | 39.2 | 1,012 |
| needle issueSignal | 23 | 47.2 | 31.8 | 996 |
| eye painSignal | 24 | 25.4 | 17.3 | 540 |
| visual impairmentSignal | 26 | 12.5 | 8.7 | 266 |
| vision blurredSignal | 22 | 9.6 | 6.4 | 162 |
| no adverse eventSignal | 24 | 7.9 | 5.4 | 139 |
| inappropriate schedule of product administrationSignal | 13 | 4.3 | 2.5 | 30 |
| off label use | 22 | 1.5 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.